No quarterly revenue total was found in ONKURE THERAPEUTICS, INC.'s SEC filings.
Onkure Therapeutics, Inc. (OKUR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$13.1 million. As of Sep 30, 2026 it held $163.3 million in cash and investments and $790,000 in total debt.
Revenue
—
Net income
$-17.85M
-21.4% vs year-ago quarter
Operating cash flow
$-13.08M
-0.3% vs year-ago quarter
Free cash flow
$-13.11M
-0.5% vs year-ago quarter
EPS
$-0.36
+67.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
40.50M
+0.0% vs prior quarter
Net cash
$162.51M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- OKUR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1637715
- Former names
- Reneo Pharmaceuticals, Inc. (until Oct 2, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$19.4M | -$16.9M | -$15.6M | -$14.1M | -$15.5M |
| Net income | -$17.8M | -$15.3M | -$15.2M | -$13.5M | -$14.7M |
| Diluted EPS | -$0.36 | -$0.31 | -$1.11 | -$0.99 | -$1.09 |
| Operating cash flow | -$13.1M | -$10.4M | -$12.9M | -$11.5M | -$13.0M |
| Free cash flow | -$13.1M | -$10.4M | -$12.9M | -$11.5M | -$13.0M |
| Total assets | $167.1M | $179.4M | $198.7M | $62.1M | $72.8M |
| Total liabilities | $9.3M | $7.2M | $14.3M | $5.9M | $6.4M |
| Stockholders' equity | $157.7M | $172.1M | $184.4M | $56.2M | $66.4M |
| Cash and investments | $163.3M | $176.4M | $192.1M | $59.0M | $70.3M |
| Total debt | $790,000 | $926,000 | $409,000 | $549,000 | $687,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 13, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
All 404 Onkure Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.